Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Non-small Cell Lung Cancer Stage I: early-phase trial registry
2 of 4 indexed Non-small Cell Lung Cancer Stage I trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 2 currently recruiting · #4,115 of 28,707 conditions by registered trial count
Non-small Cell Lung Cancer Stage I: 4 US clinical trials tracked, 2 recruiting.
Non-small Cell Lung Cancer Stage I is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 2 of these trials.
Enrollment posture brief
Registry condition non-small-cell-lung-cancer-stage-i
OPEN 2 | RECR 50% | LATE 0 | EARLY 3 | RANK #4115 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Non-small Cell Lung Cancer Stage I lists 2 open slots (50% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Non-small Cell Lung Cancer Stage I on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Non-small Cell Lung Cancer Stage I is recruiting above its size-band peers.
2 of 4 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)
Stanford University
NCT04585477
A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Disease
Memorial Sloan Kettering Cancer Center
NCT07323732
Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy
Memorial Sloan Kettering Cancer Center
NCT04716946
Pathologic and Immunologic Response After Ablative Radiation in Lung Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT03603002
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Non-small Cell Lung Cancer Stage I records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Non-small Cell Lung Cancer Stage I trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Non-small Cell Lung Cancer Stage I page
4 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Non-small Cell Lung Cancer Stage I trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Non-small Cell Lung Cancer Stage I trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Non-small Cell Lung Cancer Stage I condition card totals 4 registered trials; most-linked intervention Durvalumab; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.